arrow
E

Elisa de Stanchina

Memorial Sloan Kettering Cancer Center
H指数:94
被引数:3.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinicogenomic analysis of EGFR-mutant lung tumors identifies Rb pathway inactivation as a hallmark of squamous transformation

EGFR突变肺癌的临床基因组学分析识别出Rb通路失活是鳞状转化的标志

2026-06-170
PRE
Sensitive CAR T cells redefine targetable CD70 expression in solid tumors

敏感CAR T细胞重新定义实体瘤中可靶向的CD70表达

Science
IF45.8
2026-02-260
PRE
Patient-derived xenograft models of Fanconi anemia-associated head and neck cancer identify personalized therapeutic strategies

范可尼贫血相关头颈癌的患者来源异种移植模型识别个性化治疗策略

2026-02-160
PRE
Targeting NHEJ activates STING signaling through MYC degradation to boost antitumor immunity in SCLC

靶向NHEJ通过MYC降解激活STING信号通路以增强SCLC的抗肿瘤免疫

2026-02-100
OAAI
Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer

尿路上皮癌对HER2靶向抗体药物偶联物的敏感性决定因素

2025-12-200
OAAI
Sensitivity of metastatic mucinous tailgut cyst adenocarcinoma to gemcitabine and radiation: a case report

对转移性黏液性尾部肠囊肿腺癌对吉西他滨和放射治疗的敏感性:一篇病例报告

2025-12-190
OAAI
Editorial Expression of Concern: Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer

编辑关注声明:同时靶向IGF-1R和ALK在ALK融合阳性肺癌中的合理性

2025-11-200
OAAI
Independent mechanisms of inflammation and myeloid bias in VEXAS syndrome

VEXAS综合征中炎症和髓系偏倚的独立机制

Nature
IF48.5
2025-11-030
PRE
225Ac α-Pretargeted Radioimmunotherapy of Human Epidermal Growth Factor Receptor 2-Expressing Breast Cancer

<sup>225</sup> 靶向人表皮生长因子受体2表达型乳腺癌的α-预靶向放射免疫疗法

2025-11-011
PRE
Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas

表观遗传靶向SMARCB1缺乏性肉瘤中PGBD5依赖性的DNA损伤

2025-10-152
OA
Loss of tumor cell MHC class II drives MAPK inhibitor insensitivity ofBRAF-mutant anaplastic thyroid cancers

肿瘤细胞MHC II类分子的缺失驱动BRAF突变型间变性甲状腺癌对MAPK抑制剂的耐药性

2025-10-150
OA
Mechanical confinement governs phenotypic plasticity in melanoma

机械限制调控黑色素瘤的表型可塑性

Nature
IF48.5
2025-08-270
OAAI
Induction of a mismatch repair deficient genotype by tailored chemical mutagenesis in experimental models of cancer

在癌症实验模型中,通过定制的化学诱变诱导错配修复缺陷型基因型

2025-06-120
PRE
Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer (vol 5, 101852, 2024)

Lurbinectedin通过激活STING-IFN信号通路使PD-L1阻断疗法增敏(vol 5, 101852, 2024)

2025-02-010
OAAI
Metabolic engineering to facilitate anti-tumor immunity

代谢工程以促进抗肿瘤免疫

2025-02-011
PRE
Inhibition of NR2F2 restores hormone therapy response to endocrine refractory breast cancers

NR2F2的抑制恢复了内分泌耐药性乳腺癌对激素治疗的反应

2025-01-010
OA
Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer

Lurbinectedin通过激活STING-IFN信号通路使小细胞肺癌对PD-L1阻断疗法产生增敏作用。

2024-12-012
PRE
Concurrent SOS1 and MEK suppression inhibits signaling and growth of NF1-null melanoma

同时抑制SOS1和MEK抑制NF1-null黑色素瘤的信号传导和生长

2024-11-010
OAAI